the retest of different components ranged from 0.81 to 0.99. All hypothesized correlations with convergent measures were significant (rϾ0.40; pϽ0.01), and the MDS SS-5 discriminated between LOT-R tertiles (Fϭ24.6, pϽ0.001), SRH between doctor visits (Fϭ8.0 pϽ0.01) and TIBI between illness days (Fϭ14.9, pϽ0.001). CONCLUSIONS: Consistent with the results found in the United States, the ENSEM-BLE MDS was observed to have adequate reproducibility, appropriate convergent validity and to significantly discriminate between known groups outside the United States. OBJECTIVES: Actinic keratosis is a highly prevalent epidermal neoplastic condition among people in the United States with fair skin and a history of long term UV exposure. A new self-assessment survey-based tool was developed to help people assess their risk of either having or developing actinic keratosis. The objective of this research was to assess detailed psychometrics of the developed survey. METHODS: A test questionnaire, comprised of 10 items, was initially developed using data obtained from subjects in routine clinical practice and interviews with dermatologists. The instrument was administered along with established and validated skin health assessment instruments to 150 subjects prior to them being given a diagnosis of actinic keratosis by the dermatologist. A total of 75 subjects with a clinical diagnosis of actinic keratosis and 75 age/sex matched controls without actinic keratosis formed the sample for this study. Exploratory factor analyses, item response theory analyses, and other psychometric techniques were used to assess the reliability and validity of the Actinic Keratosis Risk Questionnaire (AKRQ). RESULTS: The final AKRQ instrument assessed was refined based on the results of exploratory factor analysis and item response techniques, ultimately limiting the scale to six items. The resulting instrument had good internal consistency (Chronbachs alpha ϭ 0.70) and correlations with other validated measures of skin quality of life (rhoϭ0.596 with the Skindex-16 and rho ϭ 0.429 with the DLQI, PϽ0.01). The sensitivity, specificity, positive and negative predictive values of the AKRQ was found to be 69.3%, 73.3%, 72.2% and 70.5% respectively. CONCLUSIONS: The AKRQ is a reliable and valid tool which may help patients self-assess their risk of either having or developing actinic keratosis based on their skin health-related behavior and quality of life symptomatology. 
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Patient satisfaction is a critical component of health care performance in all settings including pharmacy-provided services. Our study aimed to assess the validity and reliability of a newly developed survey used to evaluate patient satisfaction of an employer-sponsored medication therapy management (MTM) program provided in an independent pharmacy setting. METHODS: This exploratory study used a cross-sectional design. The survey was developed using three previous instruments and using input from practicing pharmacists. The instrument consisted of three sections (experience with the pharmacist, pharmacy, and pharmacy staff). Face validity was assessed by a review panel of practicing pharmacists and researchers. Final survey consisted of thirty-four items. A fivepoint Likert scale (1 ϭ strongly disagree to 5 ϭ strongly agree) was used. Data was collected over a one-year period and analyzed using SPSS v. 17.0. Construct validity was assessed by an exploratory factor analysis using the principal components method and a varimax rotation. Internal consistency reliability was tested using Cronbach's alpha. RESULTS: Factor analysis with varimax rotation (nϭ 171) resulted in five dimensions. Upon assessment, we labeled the factors as Experience with the Pharmacist, Experience with the Pharmacy, Experience with the Pharmacy Staff, Satisfaction of Pharmacy Care, and Prescription Promptness. The KMO measure of sampling adequacy was .954. Experience with the pharmacist accounted for 62.86% of the variance with the eigenvalue of 21.373. Cronbach's alpha for the five dimensions was found to be .977, .927, .975, .962, .868, respectively. CONCLUSIONS: Results indicate the survey demonstrates validity and reliability. With health care moving towards a more patient-centered approach and an increasing need to have patients evaluate services provided, the instrument developed for this study could serve as a valuable tool. Pharmacists may utilize this tool to assess their own MTM programs. However, additional testing in other pharmacy settings is recommended for further assessment.
PODIUM SESSION III: DRUG UTILIZATION & PRICING

UT1 THE IMPACT OF COMPARATIVE EFFECTIVENESS RESEARCH ON DRUG UTILIZATION IN THE UNITED STATES
Doyle JJ, Sepulveda B Quintiles Global Consulting, Hawthorne, NY, USA OBJECTIVES: As Comparative Effectiveness Research (CER) gains a stronger foothold in the US Healthcare system we turn our sights on the market implications of conducting "real-world" studies of the effectiveness and safety of a clinical intervention to guide evidence-based practice. Barriers to assimilation of CER in clinical decision-making may be shaped by market factors such as coverage, reimbursement, and generic availability. This analysis aims to determine what, if any, changes in prescribing patterns might have been precipitated by the findings of CER studies and examines the possible causes of such changes with respect to differences in efficacy, safety and price. METHODS: We examined prescribing patterns for drugs included in six Comparative Effectiveness Research (CER) studies -one neuroscience, one diabetes and four cardiovascular -before and after publication. Our analysis separately tracked new and refill prescriptions for the same number of quarterly intervals before and after publication of the studies analyzed, ending with Q2 (June) 2011. Drug prescription volumes and average wholesale prices (except where noted) were obtained using SDI Health's Vector One National Audit. Metrics were compared in the quarters before and after study publication. Statistical significance was defined as pϽ0.05. Analyses were performed using Microsoft Excel, two-tailed t-test. RESULTS: Drugs included in three of the six CER studies-neuroscience, diabetes and cardiovascular-showed significant changes in new, refill or total prescriptions of the drugs studies that were consistent with the published findings (i.e. positive changes following positive findings). CONCLUSIONS: Factors, in addition to the studies' findings themselves, that could have contributed to the observations include pricing of the drugs compared in the studies and generic availability. We hypothesize that factors impacting adoption of CER results in clinical practice include the number of patients enrolled and the method of dissemination of results.
UT2 IMPACT OF 2009-2011 GLOBAL HEALTH CARE REFORMS ON PRICING, ACCESS AND HEALTH OUTCOMES STRATEGY
Aggarwal S Novel Health Strategies, Bethesda, MD, USA OBJECTIVES: During 2009-2011 major health care reforms were proposed and implemented in a number of nations, for example, Affordable Care Act in the United States, AMNOG in Germany, HSPT in France, KVG in Switzerland and NHS proposed reform in the UK. These reforms have major implications on pricing, market access and HEOR strategy for drug and device products. METHODS: To understand the implications of these trends, we analyzed 2009-2011 reform bills and proposed changes worldwide. Additionally, we interviewed public and private payers, key opinion leaders and payer-influencers to understand implications of these reforms on drug and device manufacturers. Stakeholders ranked various data collection methods on a scale of 1-10 (1-least important and 10-most important).
RESULTS:
The global healthcare landscape is expected to undergo significant change during 2012-2016. In the United States, government will play increased role as a single payer, especially with?Medicare, Medicaid and CHIP programs? which will cover 114 million Americans, at a cost of $784 billion. In Germany, AMNOG bill marked the end of free drug pricing and would lead to increased insurance premiums (now 15.5% of wages). In the United Kingdom, NHS has proposed to replace PCTs with 500-1000 GP-led consortia and use value-based pricing for expensive drugs and devices. Randomized controlled trial, budget impact model and systematic reviews -ranked highest (7.5-9.1) among payers. Overall, payers view that in the future, health economic assessments would play critical role in pricing, coverage and reimbursement of branded products. CONCLUSIONS: This analysis shows that global health care landscape is expected to undergo significant change during 2012-2016. Discussions with payers, KOLs and payer-influencers highlights increased importance of HEOR data in the future.
UT3 FIRM-AND DRUG-SPECIFIC PATTERNS OF GENERIC DRUG PRICES EXPERIENCED BY UNITED STATES MEDICAID PROGRAMS: 1991-2008
Berry EA 
